BOTOX® Cosmetic and Skin Health.

Inclusion criteria

• Age above 18 years.
• Female sex.
• A SebumeterTM score >66ug/cm2 at Baseline.
• Ability to adequately understand the verbal explanations and the written subject information provided in local language and ability and willingness to give consent to participate in the study.
• Signed and dated informed consent to participate in the study and unrestricted use of facial images for marketing purpose.
• If female of childbearing potential: a negative urine pregnancy test before all treatments is required.
• Subject agrees to use the same topical cosmetic products (e.g., cleansers, moisturizers) throughout the duration of the trial, and at least for 30 days prior to enrolment.
• Subject is on a stable diet and is not planning any major dietary changes throughout the duration of the trial.
• Subject is not planning on undergoing any major hormonal changes throughout the duration of the study (e.g., menopause, change in medications).

Exclusion criteria

• Current Pregnancy or lactation [sexually active women of childbearing age must agree to use medically acceptable methods of contraception for the duration of this study (e.g., oral contraceptives, condoms, intrauterine device, shot/injection, patch)];
• Patients meeting any official BOTOX® Cosmetic contra-indications;
• Inability to comply with follow-up and abstain from other treatments in the region of interest during the study period;
• Heavy smokers, classified as smoking more than 12 cigarettes per day;
• History of severe or multiple allergies manifested by anaphylaxis;
• Previous tissue revitalization therapy in the treatment area within 6 months before treatment with laser or light, mesotherapy, radiofrequency, ultrasound, cryotherapy, chemical peeling, or dermabrasion;
• Previous treatment with neurotoxins in the area under assessment, within 6 months prior to enrolment;
• Previous treatment with soft tissue fillers in the area under assessment, within 6 months prior to enrolment;
• Subjects presenting with known allergy to BOTOX® Cosmetic.
• Subjects presenting with porphyria.
• Subjects with active disease, such as inflammation, infection or tumors, in or near the intended treatment site.
• History of bleeding disorders or treatment with thrombolytics, anticoagulants, or inhibitors of platelet aggregation (e.g. Aspirin or other non-steroid anti-inflammatory drugs [NSAIDs]), within 2 weeks before treatment.
• Subjects using immunosuppressants.
• Subjects prescribed systematic or topical (in the area under assessment) antibiotics within 1 month of enrolment.
• Tattoos, piercings or visible markings that in the treating investigator's opinion, may interfere with results or assessments.
• Cancer or precancer in the treatment area, e.g. actinic keratosis.
• Patients with a tendency to form hypertrophic scars or any other healing disorders.